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Abstract
A high-dose, accelerated escalation schedule during subcu-
taneous allergen-specific immunotherapy (AIT) is safe and 
well-tolerated in adults. However, there are no data in chil-
dren and adolescents. The aim of the present trial was to as-
sess safety and tolerability of an accelerated dose escalation 
schedule of an AIT with a grass pollen allergoid in children 
and adolescents with moderate to severe seasonal rhino-
conjunctivitis in a multicenter, open-label, randomized 
phase II trial. The dose escalation scheme for patients in the 
One Strength Group included 3 injections with 1 strength B 
(10,000 TU/mL), whereas the dose escalation scheme for the 
Standard group included 7 injections with 2 strengths A 
(1,000 TU/mL) and B (10,000 TU/mL) of an allergoid grass pol-
len preparation. Overall, n = 50 children (n = 25 in each 
group; mean age 8.9 + 1.54 years) and n = 37 adolescents 
(n = 20 and n = 17; 14.2 + 1.62 years) were randomized. For 
all patients, the mean treatment duration was 59.4 days in 
the One Strength group and 88.6 days in the Standard group. 
Treatment-emergent adverse events (TEAEs) related to AIT 
were reported in 52 and 40% in children and 35 and 35.3% 
in adolescents, respectively. Systemic allergic reactions oc-
curred in about 5% of our patients and were reported in 
more patients of the One Strength group (6.7 vs. 2.4%). All 
systemic reactions were classified as WAO Grade 1. Acceler-
ated high-dose escalation with an aluminum hydroxide-ad-
sorbed grass pollen allergoid can be initiated with a safety 
and tolerability profile comparable to the standard dose es-
calation schedule in children and adolescents with allergic 
rhinitis with or without asthma. © 2021 The Author(s)
Published by S. Karger AG, Basel
Edited by: H.-U. Simon, Bern.
This is an Open Access article licensed under the Creative Commons 
Attribution-NonCommercial-4.0 International License (CC BY-NC) 
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Introduction
Allergen-specific immunotherapy (AIT) is the spear-
head of our limited arsenal of sustainable treatment op-
tions fighting the epidemic of allergic diseases [1]. For 
allergic rhinitis (AR) and/or allergic asthma, sublingual 
and subcutaneous administration of AIT has been shown 
to be efficacious and saves treatment options. However, 
the acceptance and adherence of subcutaneous AIT is 
limited by long-term updosing and maintenance phases 
[2]. During the last years, a number of clinical trials be-
came available demonstrating that accelerated high-dose 
escalation schedules can be applied in patients with AR 
with or without asthma with a comparable safety and tol-
erability profile as the standard escalation schedules. Re-
cently, Chaker et al. [3] have demonstrated that an accel-
erated 4-dose escalation scheme of a grass pollen allergoid 
starting with 200 therapeutic units (TU) can be given with 
a beneficial safety profile comparable to the standard 
7-dose escalation regime starting with 100 TU. Taking a 
step forward, we were able to demonstrate that also an ac-
celerated high-dose escalation schedule of a grass pollen 
allergoid starting with a 5 times higher initial dose (1,000 
TU) can be safely administered. Eighty percent of the pa-
tients in the high-dose escalation group reached the first 
AIT injection of the maintenance phase without dose ad-
justment [4]. While a slightly higher number of patients 
in the high-dose escalation group reported systemic al-
lergic reactions (n = 4; 8.9%) compared to the standard 
dose escalation group (n = 1; 2.4%), all systemic allergic 
symptoms were classified as mild (WAO Grade 1 or 
Grade 2). However, all these observations are limited to 
adult populations and data in the pediatric and adoles-
cent subgroups are sparse. Therefore, we performed a 
multicenter, open-label, randomized phase II clinical tri-
al in pediatric patients with rhinitis or rhinoconjunctivitis 
caused by grass pollen sensitization and applied two dif-
ferent updosing regimes of a grass pollen allergoid.
Methods
Patients
This multicenter, open-label, randomized, parallel, active-con-
trolled phase II trial was conducted in pediatric patients (5 to <18 
years of age) with rhinitis or rhinoconjunctivitis caused by grass 
pollen. Patients between 5 and <18 years of age with the diagnosis 
of immunoglobulin E (IgE)-mediated seasonal moderate to severe 
AR according to the Allergic Rhinitis and its Impact on Asthma 
(ARIA) guideline [5] or rhinoconjunctivitis with or without aller-
gic asthma caused by grass pollen could be enrolled after providing 
informed consent. Further inclusion criteria included a positive 
skin prick test (≥3 mm in diameter) and specific IgE (≥0.70 kU/L) 
against grass pollen. In addition, patients had to experience AR or 
rhinoconjunctivitis symptoms triggered by grass pollen exposure 
for at least 1 month in the period from May to August, and they 
had to receive previous antiallergic treatment for at least two sea-
sons prior to enrollment. In cases with a diagnosis of asthma, the 
asthma had to be diagnosed and classified as “well-controlled” ac-
cording to the Global Initiative for Asthma (GINA) guideline [6]. 
Exclusion criteria included prior history of confirmed anaphylax-
is after an AIT injection with grass pollen within the last 5 years, 
current treatment with any kind of immunotherapy, and uncon-
trolled/partly controlled asthma according to the Global Initiative 
for Asthma (GINA) guideline. Moreover, patients with autoim-
mune diseases, β-blocker use, and contraindication for the use of 
adrenalin could not be enrolled.
Patients were randomized into a group with accelerated dose 
escalation (Group I or “One Strength group”) and a group with 
standard dose escalation (Group II or “Standard group”) in a 1:1 
ratio within each site. In order to achieve a balanced distribution 
of patients within each treatment group according to the two dif-
ferent age-groups (5 to <12 years and 12 to <18 years), patients 
were stratified according to their age.
The trial was conducted in autumn and winter, that is, prior to 
the grass pollen season. All patients were recruited between Octo-
ber 2018 and March 2019. No placebo group was included in this 
trial (EudraCT 2018-000548-25).
Trial Design and Treatment
This was a multicenter, open-label, randomized, parallel, ac-
tive-controlled phase II trial in pediatric patients with rhinitis or 
rhinoconjunctivitis caused by grass pollen. It was conducted in 
Germany, Poland, Russia, and Spain.
The grass pollen allergoid (Allergovit® 6-grasses; Allergophar-
ma GmbH and Co. KG, Reinbek, Germany) contains a mixture of 
allergens from 6 grass pollen species (Holcus lanatus, Dactylis 
glomerata, Lolium perenne, Phleum pratense, Poa pratensis, and 
Festuca pratensis). The allergoid is coprecipitated with aluminum 
hydroxide. The preparation is provided in two strengths: A (1,000 
TU/mL) and B (10,000 TU/mL). The approximate estimation of 
major allergen content for Phleum pratense (Phl p 5) is 25 μg equiv-
alent/mL in Allergovit® 6-grasses (in strength 10,000 TU) [7].
The One Strength group received 3 injections of one strength 
(B) of the grass pollen allergoid (0.1 mL of 1,000 TU, 0.3 mL of 
3,000 TU, and 0.6 mL of 6,000 TU) at weekly intervals. The Stan-
dard group started with 1/10 of the dose of the One Strength group 
and received 7 injections (strength A: 0.1 mL of 100 TU, 0.2 mL of 
200 TU, 0.4 mL of 400 TU, and 0.8 mL of 800 TU; strength B: 0.15 
mL of 1,500 TU, 0.3 mL of 3,000 TU, and 0.6 mL of 6,000 TU). 
When the maintenance dose had been reached, both groups re-
ceived 2 maximum-dose injections (0.6 mL of 6,000 TU) of 
strength B after 14 and 28 days. After each injection, patients in 
both groups were supervised for at least 120 min to monitor po-
tential adverse reactions. Dosage modification was performed if 
local and/or systemic adverse events (AEs) occurred, based on a 
predefined regime. The WAO grading system was used to decide 
on dose modification in case of an systemic reaction. Briefly, if the 
patient experienced a systemic allergic reaction of any WAO grade 
following the first injection or a WAO Grade 3 or 4 reaction, then 
the patient must be discontinued from the trial. A WAO Grade 1 
reaction resulted in a reduction by 1 dose step of the last applied 
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dose; a WAO Grade 2 resulted in a reduction by 2 dose steps of the 
last applied dose. If the first dose reduction was not tolerated in 
case of a WAO Grade 1 or 2 reaction, a second dose reduction by 
1 dose step of the last applied dose was administered. No more than 
2 dose reductions per patient due to an AE were tolerated during 
the trial.
Assessment of AR and Asthma
To assess the severity of the patient’s AR, the symptomatic his-
tory according to the Allergic Rhinitis and its Impact on Asthma 
(ARIA) guideline was documented by the investigator at the 
screening visit. Peak flow measurements were also performed. The 
asthma status of all patients was monitored by the Asthma Control 
Questionnaire.
Assessment of Safety and Tolerability End Points
Safety and tolerability end points focused on treatment-emer-
gent AEs (TEAEs), defined as any AE that started or worsened af-
ter the first intake of trial medication until 30 days after the last 
administration of the investigational medicinal product (IMP) or 
trial-related procedure. An adverse drug reaction was defined as 
all untoward and unintended responses to the IMP related to any 
dose administered. A local adverse reaction was defined as an AE 
related or not related to the IMP and occurring at the injection site. 
A systemic allergic reaction was defined as an AE related or not 
related to the IMP and graded as systemic according to the WAO 
grading system based on the organ systems involved and the sever-
ity of the reaction.
Apart from AE data, changes in laboratory values (hematology, 
clinical chemistry, and urinalysis) measured before and after the 
treatment phase, changes in vital signs and lung function mea-
sured before and after the treatment phase, and the assessment of 
overall tolerability, by the investigator and the patient, using a 
5-point Likert scale (1 = very bad; 5 = very good) were document-
ed. The trial was supervised by an independent Data and Safety 
Monitoring Board.
Statistical Analysis
Due to the exploratory design of the trial, there was no formal 
estimation of sample size. It was planned to randomize 35 patients 
per age and treatment group, which equals a total of 140 patients 
(children/adolescents and group I [One Strength]/group II [Stan-
dard]), to guarantee a probability of 95% that AEs with a true in-
cidence rate of 8.6% occur at least once in the respective treatment 
group [8].
The patients were assigned to the following sets before starting 
the analysis: the “All-Patients Set” comprised patients that gave 
their informed consent. For this group, the patients’ disposition 
and reasons for premature trial termination are described. The 
“Safety Set” (SAF) was the group of patients who received at least 
1 dose of trial medication. It is the basic analysis set for all assess-
ments of safety and tolerability. For this set, exposure to IMP was 
analyzed.
Numbers and incidence rates of AEs and severe AEs with caus-
al relationship to the IMP are reported separately for both age-
groups. Statistical tests (Fisher’s exact test, χ2 test, and Wilcoxon-
Mann-Whitney U test) were performed when adequate. Other-
wise, the analysis was performed descriptively and explained by 
comparing events and frequencies between groups. For all statisti-
cal tests, a significance level of α = 5% was chosen.
Results
Patients
A total of 115 patients (children and adolescents) were 
enrolled in this trial, 60 children and 55 adolescents. Of 
the 60 screened children, 50 were randomized (safety set), 
25 patients to the One Strength group and 25 patients to 
the Standard group (Fig. 1). A total of 3 randomized pe-
diatric patients prematurely discontinued the trial, 1 in 
the One Strength group (AE: injection site swelling) and 
2 in the standard group (AE: varicella and other reasons). 
In total, 37 adolescent patients were randomized, 20 pa-
tients to the One Strength group and 17 patients to the 
Standard group (Fig. 1). Two adolescent patients prema-
turely discontinued the trial, 1 in the One Strength group 
(AE: urticaria) and 1 in the Standard group (personal rea-
sons).
For both children and adolescents, demographic char-
acteristics were generally comparable between groups 
(Table 1). The incidence of patients’ allergy-specific his-
tory was generally comparable between groups. Almost 
all pediatric patients experienced nasal (98.0%) and ocu-
lar symptoms (86.0%). Wheezing, shortness of breath, 
and cough was reported for nearly half of the patients 
(ranged from 40.0 to 46.0%); chest tightness was reported 
for 32.0% of the pediatric patients (see online suppl. Table 
1; see www.karger.com/doi/10.1159/000512561 for all 
online suppl. material). The mean and median duration 
of symptoms was generally comparable between the 
groups. All adolescent patients experienced nasal symp-
toms, and the majority of patients experienced ocular 
symptoms (78.4%). Wheezing, shortness of breath, and 
cough was reported for about one-sixth of the patients 
(ranged from 16.2 to 18.9%); chest tightness was reported 
for 13.5% of the adolescent patients. The incidence of pa-
tients’ allergy-specific history was generally comparable 
between groups; incidence in wheeze (25.0 vs. 11.8%), 
shortness of breath (30.0 vs. 5.9%), and chest tightness 
(20.0 vs. 5.9%) was higher in the One Strength group than 
in the Standard group.
For both children and adolescents, immunological 
profiles (total and specific IgE, i.e., mugwort, rye, birch, 
P. pratense, grass mix/early bloom, D. farinae, and D. 
pteronyssinus) did not differ significantly between treat-
ment groups at baseline (Table 1). In the One Strength 
group, the majority of patients received 5 injections in 
total (children: 92.0%; adolescents: 85.0%) and in the 
standard group, 9 injections (children: 80.0%; adoles-
cents: 94.1%). Accordingly, the median treatment dura-
tion was shorter in the One Strength group compared to 
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that in the Standard group for children (One Strength 
group: 61 days; Standard group: 87 days) and adolescents 
(One Strength group: 61 days; Standard group: 85 days). 
Median compliance was 100% for children and adoles-
cents in both treatment groups.
Adverse Events
Overall, n = 51 (58.6%) patients reported at least 1 
TEAE. The proportion of patients with at least 1 TEAE 
during the trial was similar in both groups (One Strength 
group: 60.0%; Standard group: 57.1%).
In the subgroup of children, n = 34 (68.0%) patients 
reported at least one TEAE (Table 2). The proportion of 
pediatric patients with at least one TEAE during the trial 
was slightly higher in the One Strength group than in the 
Standard group (72.0 vs. 64.0%; p = 0.7624). In the sub-
group of adolescents, 17 (45.9%) patients reported at least 
one TEAE. The proportion of adolescent patients with at 
least one TEAE during the trial was similar between 
groups (One Strength group: 45.0%; Standard group: 
47.1%; p = 1.0000; Table 2).
AE: adverse event; APS: All-patients set; disc.: discontinued; SAF: Safety set
1 Screening failures were due to not meeting inclusion and/or exclusion criteria, withdrawal of consent, or 
other reasons
2 Premature discontinuations were due to AEs or other reasons
3 Patients were assigned to the SAF as treated
4 Completed patients are those patients who did not discontinue the trial prematurely
Enrolled patients 
APS 
n = 60 children 
n = 55 adolescents 
Screening failures1
n = 10 children 
n = 18 adolescents 
One Strength 
n = 25 children 
n = 20 adolescents 
Premature disc.2
n = 1 child 
n = 1 adolescent 
SAF3
n = 25 children 
n = 20 adolescents 
Completed patients4
n = 24 children 
n = 19 adolescents 
Premature disc.2
n = 2 children 
n = 1 adolescent 
SAF3
n = 25 children 
n = 17 adolescents 
Standard 
n = 25 children 
n = 17 adolescents
Completed patients4
n = 23 children 
n = 16 adolescents 
Randomized patients 
n = 50 children 
n = 37 adolescents 
Fig. 1. Disposition of patients. AE, adverse event; APS, all-patients set; Disc., discontinued; SAF, safety set.
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Mean (SD) 8.9 (1.76) 8.9 (1.32) 13.9 (1.41) 14.6 (1.80)
Median 9.0 9.0 14.0 15.0
Min.–max. 5–11 6–11 12–16 12–17
Gender, n (%)
Male 15 (60.0) 17 (68.0) 14 (70.0) 9 (52.9)
Female 10 (40.0) 8 (32.0) 6 (30.0) 8 (47.1)
Asthma (yes), n (%) 15 (60.0) 14 (56.0) 5 (25.0) 3 (17.6)
Among them, n (%)
Inhaled steroids (yes) 13 (86.7) 10 (71.4) 3 (60.0) 3 (100)
Inhaled steroids (no) 2 (13.3) 4 (28.6) 2 (40.0) 0
Ethnicity, n (%)
White 25 (100) 25 (100) 20 (100) 17 (100)
BMI, kg/m2
Mean (SD) 17.7 (2.46) 18.3 (3.95) 20.0 (3.24) 20.6 (3.35)
Median 17.5 17.1 19.5 20.0
Min.–max. 13–22 13–29 15–29 17–29
Pet contact, n (%)
No 20 (80.0) 19 (76.0) 14 (70.0) 11 (64.7)
Intermittent 3 (12.0) 0 0 0
Permanent 2 (8.0) 6 (24.0) 6 (30.0) 6 (35.3)
Total IgE, kU/L
Median 352.00 428.00 262.50 220.00
Min.–max. 16.2–845.0 55.0–3,615.0 37.8–6,734.0 58.6–3,113.0
Specific IgE, kU/L for grass mix/early bloom
Median 32.500 45.600 16.300 27.500
Min.–max. 1.39–100.00 0.76–100.00 0.71–100.00 1.30–100.00
Specific IgG4 for Phleum pratense, mg/L
Median 0.240 0.340 0.250 0.330
Min.–max. 0.07–1.79 0.07–6.28 0.07–0.93 0.07–1.57
N, number of patients; n (%), number (percentage) of patients with data; SAF, safety set.










n (%) e n (%) e n (%) e n (%) e
TEAEs 18 (72.0) 59 16 (64.0) 58 9 (45.0) 55 8 (47.1) 43
TEAEs related to IMP 13 (52.0) 21 10 (40.0) 27 7 (35.0) 39 6 (35.3) 32
Local reactions 10 (40.0) 16 10 (40.0) 27 6 (30.0) 36 5 (29.4) 25
Systemic allergic reactions 2 (8.0) 2 0 0 1 (5.0) 1 1 (5.9) 5
Other type of events 14 (56.0) 41 10 (40.0) 31 6 (30.0) 18 5 (29.4) 13
TEAEs leading to discontinuation 1 (4.0) 3 1 (4.0) 1 1 (5.0) 1 0 0
Treatment-emergent SAE 0 0 0 0 1 (5.0) 1 1 (5.9) 5
Treatment-emergent SAE related to IMP 0 0 0 0 1 (5.0) 1 1 (5.9) 5
e, number of events (TEAEs); IMP, investigational medicinal product; n, number of patients; n (%), number (percentage) of patients 
with at least one TEAE; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
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In the subgroup of children, of the 117 reported 
TEAEs, 48 TEAEs were assessed as related to IMP by the 
investigators and occurred in 23 (46.0%) patients. Slight-
ly more pediatric patients experienced at least one IMP-
related TEAE in the One Strength group than in the Stan-
dard group (52.0 vs. 40.0%; p = 0.5709) with slightly 
smaller absolute and relative number of events in the 
One Strength group than in the Standard group (21 vs. 
27, ratio of TEAE per patient: 1.6 vs. 2.7). In the subgroup 
of adolescents, of the 98 reported TEAEs, 71 TEAEs were 
assessed as related to IMP by the investigators and oc-
curred in 13 (35.1%) patients. The number of adolescent 
patients who experienced at least one IMP-related TEAE 
was comparable between groups (One Strength group: 
35.0%; Standard group: 35.3%; p = 1.0000) with slightly 
more events in the One Strength group than in the Stan-
dard group (39 vs. 32, ratio of TEAE per patient 5.6 vs. 
5.3). An overview of TEAEs related to the IMP is pre-
sented in Table 3 for the subgroup of children and ado-
lescents.
For both children and adolescents, most of the report-
ed TEAEs related to IMP were local reactions: 105 local 
reactions were reported with an equal distribution in both 
groups (One Strength group: 53 TEAEs; Standard group: 
52 TEAEs). The number of affected patients was similar 
between both groups (One Strength group: 35.6%; Stan-
dard group: 35.7%; p = 1.0).










n (%) e n (%) e n (%) e n (%) e
Overall 13 (52.0) 21 10 (40.0) 27 7 (35.0) 39 6 (35.3) 32
Mild 18 25 27 29
Moderate 3 2 12 3
Severe 0 0 0 0
General disorders and administration site conditions 10 (40.0) 17 10 (40.0) 27 6 (30.0) 36 5 (29.4) 25
Injection site swelling 8 (32.0) 11 8 (32.0) 11 5 (25.0) 13 4 (23.5) 10
Injection site erythema 2 (8.0) 3 3 (12.0) 11 3 (15.0) 11 3 (17.6) 7
Injection site pruritus 2 (8.0) 2 3 (12.0) 3 4 (20.0) 8 2 (11.8) 8
Injection site edema 0 0 1 (4.0) 1 0 0 0 0
Injection site pain 0 0 1 (4.0) 1 3 (15.0) 3 0 0
Swelling 1 (4.0) 1 0 0 0 0 0 0
Injection site discomfort 0 0 0 0 1 (5.0) 1 0 0
Investigations 1 (4.0) 1 0 0 0 0 0 0
Forced expiratory volume decreased 1 (4.0) 1 0 0 0 0 0 0
Musculoskeletal and connective tissue disorders 1 (4.0) 1 0 0 0 0 0 0
Pain in extremity 1 (4.0) 1 0 0 0 0 0 0
Nervous system disorders 1 (4.0) 1 0 0 0 0 1 (5.9) 2
Headache 1 (4.0) 1 0 0 0 0 1 (5.9) 1
Somnolence 0 0 0 0 0 0 1 (5.9) 1
Respiratory, thoracic and mediastinal disorders 0 0 0 0 2 (10.0) 2 1 (5.9) 1
Cough 0 0 0 0 0 0 1 (5.9) 1
Rhinitis, allergic 0 0 0 0 1 (5.0) 1 0 0
Sneezing 0 0 0 0 1 (5.0) 1 0 0
Skin and subcutaneous tissue disorders 1 (4.0) 1 0 0 1 (5.0) 1 1 (5.9) 2
Dermatitis, allergic 1 (4.0) 1 0 0 0 0 0 0
Urticaria 0 0 0 0 1 (5.0) 1 1 (5.9) 1
Pruritus 0 0 0 0 0 0 1 (5.9) 1
Eye disorders 0 0 0 0 0 0 1 (5.9) 1
Conjunctival edema 0 0 0 0 0 0 1 (5.9) 1
Infections and infestations 0 0 0 0 0 0 1 (5.9) 1
Rhinitis 0 0 0 0 0 0 1 (5.9) 1
e, number of events (TEAEs); IMP, investigational medicinal product; n, number of patients; n (%), number (percentage) of patients with at least one 
TEAE; PT, preferred term; SAF, safety set; SOC, system organ class; TEAE, treatment-emergent adverse event.
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In the subgroup of children, 44 local reactions related 
to IMP occurred slightly less frequently in the One 
Strength group than in the Standard group (17 vs. 27 
TEAEs). The number of affected patients was equal in 
both groups (One Strength group: 40.0%; Standard group: 
40.0%; p = 1.0). In the subgroup of adolescents, 61 local 
reactions related to IMP occurred slightly more frequent-
ly in the One Strength group than in the Standard group 
(36 vs. 25 TEAEs). The number of affected patients was 
similar between both groups (One Strength group: 30.0%; 
Standard group: 29.4%; p = 1.0).
No deaths and no suspected unexpected serious ad-
verse reactions were reported during the trial. Only in the 
subgroup of adolescents, serious AEs occurred in 1 pa-
tient of the One Strength group and another patient of the 
Standard group. Overall, 3 patients experienced TEAEs 
leading to premature discontinuation from the trial (One 
Strength group: 2 patients, Standard group: 1 patient). 
One adolescent in the One Strength group suffered from 
a systemic allergic reaction (urticaria) which was related 
to study medication. One child in the One Strength group 
suffered from non-serious adverse drug reactions (injec-
tion site swelling, swelling, and pain) which were related 
to study medication. Another child in the Standard group 
suffered from a non-serious AE (varicella) which was not 
related to study medication. All these patients were in-
cluded in final computation.
Systemic Adverse Reactions
Overall, systemic allergic reactions occurred in 4 
(4.6%) patients, 3 (6.7%) patients in the One Strength 
group and 1 (2.4%) in the Standard group (p = 0.6171). In 
the subgroup of children, 2 systemic allergic reactions re-
lated to IMP occurred in 2 patients, all of which were re-
ported in the One Strength group: forced expiratory vol-
ume decreased and allergic dermatitis. There was no sta-
tistically significant difference between groups (p = 0.49). 
Both systemic allergic reactions in pediatric patients were 
assessed as non-serious.
In the subgroup of adolescents, 6 systemic allergic re-
actions related to IMP occurred in 2 patients. Of the 6 
reported events, 1 (urticaria) occurred in 1 patient of the 
One Strength group, and 5 systemic TEAEs were reported 
from 1 patient of the Standard group. The allergic reac-
tions were conjunctival edema, cough, pruritus, rhinitis, 
and urticaria. There was no statistically significant differ-
ence between groups. All 6 systemic allergic reactions in 
adolescent patients were assessed as serious.
Time to Onset of TEAEs Related to IMP
Overall, most of the TEAEs related to IMP were re-
ported during these escalation phases. For both children 
and adolescents in the One Strength group, most IMP-
related TEAEs occurred after the second IMP administra-
tion with a decrease in the number of IMP-related TEAEs 
with further IMP injections (Fig. 2). In contrast, for chil-






















2 3 4 5 6 7 8 9 10 11 12 13
Occurrence of TEAEs related to IMP in relation to individual IMP administration, weeks
14 15 16 17 18 19 20 21 22 23 24 25
■ One strength    ■ Standard
Fig. 2. TEAEs related to IMP in relation to individual injections – pooled analysis (children, adolescents, and 
adults). IMP, investigational medicinal product; TEAE, treatment-emergent adverse event.
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of IMP-related TEAEs after the first and second IMP dos-
es was lower compared to the One Strength group; here, 
the peak of IMP-related TEAEs occurred between the 
fifth and seventh IMP injection.
For both children and adolescents, most of the IMP-
related TEAEs occurred up to 6 h after IMP administra-
tion (children: 30 of 48 TEAEs; adolescents: 48 of 71 
TEAEs). In the subgroup of children, a slightly fewer 
number occurred in the One Strength group than in the 
Standard group (12 TEAEs vs. 18 TEAEs). In the sub-
group of adolescents, a slightly higher number occurred 
in the One Strength group than in the Standard group (28 
TEAEs vs. 20 TEAEs). In children and in adolescents, af-
ter 6 h, the number of TEAEs decreased continuously. 
Further analyses suggest that there was no influence of 
the reaction type (local reaction or systemic allergic reac-
tion) on the time to onset, neither in children nor in ado-
lescents. A more detailed analysis of the onset period >30 
min to ≤6 h in both populations revealed that the major-
ity of TEAEs related to IMP occurred up to 2 h (children) 
and 3 h (adolescents), respectively, after IMP injection.
Tolerability and Other Safety Parameters
All investigators (children) and the majority of inves-
tigators (adolescents), respectively, assessed the overall 
tolerability at the end of the escalation phase as “very 
good” or “good” (children: 75.0 and 25.0%; adolescents: 
80.6 and 13.9%, Fig. 3). Similar results were obtained for 
the patient’s assessment (children: 87.5 and 12.5%; ado-
lescents: 80.6 and 16.7%). The investigators judged the 
tolerability for children in the One Strength group after 
the last dose of the escalation phase slightly inferior to the 
Standard group (very good: 62.5 vs. 87.5%). This differ-
ence was statistically significant (p = 0.0494). All other 
assessment results were similar for both the One Strength 
group and the Standard group (p > 0.05). Furthermore, 
the investigators’ and patients’ assessments at the final 
visit revealed similar results.
For all patients (children and adolescents), there were 
no notable differences between the asthmatic and non-
asthmatic patients. Furthermore, there were no clinically 
relevant differences between the treatment groups in 
terms of changes in clinical chemistry, hematology, and 
urinalysis values during the trial. The immunological 
profile was assessed at baseline and at the final visit. Dur-
ing the course of the trial, the mean amount of IgG4 
against Timothy grass pollen increased notably over time 
in both treatment groups for children and adolescents 
(p < 0.0001). The comparison of the mean changes from 
baseline revealed no notable difference between treat-
ment groups at final visit for children and adolescents 
(p > 0.05).
Discussion
Administration of grass pollen allergoid preparations 
using the standard dose escalation scheme is an effica-
cious and safe treatment option in children and adoles-
cents with AR and/or allergic asthma [9]. The use of al-
ternative dose escalation schemes with fewer injections is 
increasingly common in daily practice. Since reported re-
actions were mainly local and mild of intensity, the use of 
an accelerated dose escalation should be expected to be 
safe and comparable to standard schemes with regard to 
the appearance, frequencies, and severity of side effects 
[10]. However, up to now, there are only limited data 
about side effects of shortened escalation schemes with 
higher injection doses in children and adolescents. In this 
open-label, randomized, active-controlled trial, we were 
able to demonstrate that an accelerated high-dose escala-
tion schedule using 3 injections of a grass pollen allergoid 
can be applied with a comparable safety profile as the 
standard escalation schedule using 7 injections. Nearly 
90% of all randomized patients reached the first AIT in-
jection of the maintenance phase without dose adjust-


















Fig. 3. Assessment of overall tolerability in the two groups by the 
investigator after the last dose of the escalation phase on a 5-point 
Likert scale (very bad – bad – average – good – very good).
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ment. Moreover, the overall tolerability at the end of the 
escalation phase was assessed as “very good” or good” by 
the majority of investigators and patients. Altogether, our 
results point toward a favorable safety profile of the ac-
celerated updosing scheme.
For all patients, children, and adolescents, most of the 
reported TEAEs related to AIT were local reactions with 
an equal distribution in both groups. Local reactions from 
AIT are common during the updosing and maintenance 
phase [11]. In our study, not only the absolute number of 
TEAS but also the number of affected patients was similar 
between both groups. Overall, the most commonly re-
ported local reactions related to AIT were injection site 
swelling, followed by injection site erythema and injec-
tion site pruritus. These data fit precisely with the results 
of our recently published clinical trial in adults [4]. How-
ever, all local symptoms were reported more frequently 
in adults compared to children and adolescents. The local 
side effects of the grass pollen allergoid was in the lower 
quartile compared with data from recently published 
studies, showing that as many as 26–86% of the patients 
receiving SCIT experience local reactions [12].
Systemic allergic reactions occurred in about 5% of our 
patients and were reported in more patients of the One 
Strength group (6.7 vs. 2.4%). Again, these data are in line 
with data published in adults [4, 12]. In our population, 
all systemic allergic reactions were classified as WAO 
Grade 1 reactions. All pediatric and adolescent patients 
reported TEAEs of mild or moderate intensity, and no 
TEAE was classified as severe. The frequency and the in-
tensity of TEAEs were overall not considered a safety con-
cern, and no change in the benefit risk profile of the me-
dicinal product was regarded necessary.
Current asthma guidelines now recommend sublin-
gual and/or subcutaneous AIT as an add-on therapy for 
asthma in adults and children based on results from re-
cent clinical studies [6, 13]. However, uncontrolled asth-
ma is still a contraindication for AIT, and patients with 
asthma are believed to be at higher risk for systemic side 
effects [14]. With respect to the subpopulation of asth-
matic patients, our analyses revealed that there were no 
significant safety signals or other findings compared to 
the whole trial population. Nevertheless, our subgroup 
comprised only 29 children and 8 adolescents with AR 
and asthma. Even if our results are in line with recently 
collected data in adults [4], a larger population must be 
recruited to make a valid and evidence-based conclusion 
for asthmatic patients in this age-group.
A number of clinical studies have shown that func-
tional IgG4 antibodies are induced by AIT [15]. We hy-
pothesize that an accelerated dose schedule might offer 
the opportunity to gain clinical and immunological toler-
ance faster compared to standard dose escalation. There-
fore, we assessed the change of specific IgG4 for P. pratense 
between the screening visit and the final visit as an explor-
atory end point. For children and adolescents, the mean 
amount of IgG4 against Timothy grass pollen increased 
significantly over time in both groups. The comparison 
between both groups revealed slightly higher IgG4 con-
centration in the One Strength group; however, this dif-
ference was not statistically significant.
Recently, Zissler et al. [16] reported data of an obser-
vational real-life, case-controlled, and long-term clinical 
cohort. They proposed 3 phases of the tolerogenic process 
during AIT and reported a correlation of the ratio of IL-
10+ B-cells and Th17 cells during the early initiation 
phase to symptom improvement after 3 years of treat-
ment. The hypothesis of a different tolerogenic effect 
might be supported by the clinical observation of a spe-
cific pattern of AEs in relation to the number of the indi-
vidual injection. While the highest number of AEs in the 
high-dose escalation group occurred after the first and 
second injections in weeks 1 and 2, the number of AEs 
peaked in the standard dose escalation group in weeks 5 
and 6. Hypothetically, these data might point toward a 
faster tolerance induction in the high-dose escalation 
group.
Beyond clinical trials, adherence to both subcutaneous 
and sublingual AIT is limited. Recently, Kiel et al. [2] 
showed that real-life persistence is better in subcutaneous 
AIT than in sublingual AIT in the Netherlands with 23 
and 7% of the users that reached the optimal duration of 
treatment of 3 years, respectively. One potential barrier 
that might be opposed to a better adherence to AIT is the 
length of treatment. In this context, the advantage of a 
shortened AIT therapy is that administration of fewer in-
jections is comfortable and more convenient for the pa-
tients having fewer visits in doctor’s practice. In addition, 
less absenteeism from school or from leisure activities of 
children and adolescents is especially relevant for pediat-
ric patients. For all patients in our trial, the mean treat-
ment duration was 59.4 days in the One Strength group 
compared to 88.6 days in the Standard group.
An additional aspect of better adherence to AIT is the 
concept of “shared decision-making” [17]. Applied to AIT 
administration, health-care providers keep information 
on treatment options, that is, conventional versus acceler-
ated updosing regimes of AIT and their potential benefits 
and harms. The patients’ perspective addresses the cur-
rent social situation and lifestyle preferences. Putting 
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might initiate a process of shared decision-making. Future 
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good safety profile in our high-dose escalation group.
In conclusion, our results show that regardless of dos-
ing schedule, AIT with grass pollen allergoid was safe and 
well-tolerated in children and adolescents with rhinitis or 
rhinoconjunctivitis with or without comorbid asthma. 
TEAEs were comparable between high-dose and stan-
dard dose escalation and predominantly local reactions. 
Systemic reactions were observed in about 5% in the One 
Strength group, but all of them were graded as WAO 
Grade 1. Altogether, the accelerated updosing scheme 
with a grass pollen allergoid offers an additional treat-
ment option of AIT in children, adolescents, and adults.
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